Every 3rd Indian affected by some metabolic dysfunction, mass level awareness needed: Minister
Addressing the Foundation Day ceremony of the Research Society for Study of Diabetes in India (RSSDI), Singh expressed concern that India continues to be labelled the 'diabetes capital of the world'.
'Every third Indian is affected by some form of metabolic dysfunction,' he said.
The Minister, himself a globally renowned endocrinologist, also cautioned against diabetes disinformation, which tends to be spread, sometimes inadvertently, from certain quarters.
He debunked popular myths, such as the belief in 'one meal a day', urging for a more scientific understanding of meal quality and quantity in diabetes care.
Singh reiterated the target of reducing non-communicable diseases (NCDs) by 10 per cent, particularly those associated with fatty liver, visceral fat, and obesity.
He emphasised that public health messaging must go beyond medical publications and into institutionalised outreach to common citizens.
Calling for evidence-based health awareness, Singh gave a firm dictum: 'Treat diabetes before it occurs, stressing that prevention is better than cure'.
Recently, Singh also launched a study led by RSSDI, which showed that yoga can reduce the risk of diabetes by 40 per cent, highlighting the potential of yoga in preventive healthcare.
The study suggested that the regular practice of yoga may reduce the risk of developing Type 2 diabetes by as much as 40 per cent in individuals predisposed to the condition.
"This is one of the first such efforts that seeks to scientifically document the prevention of the occurrence of Type 2 diabetes with yoga. As per the authors of the report, there is as much as a 40 per cent reduction in the development of Type 2 diabetes among potential individuals who practice yoga regularly," Singh said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
31 minutes ago
- Time of India
Why are Indian households struggling with medical costs despite health initiatives?
India had one of the highest out-of pocket (OOP) health expenditures as a percentage of total health expenditure among major economies in 2024, despite a decline from over 60% in 2014 to under 40% estimated in 2024. At the same time China's OOP share dropped slightly from over 36% to 32% over the same period. HEALTH PROTECTION GAP Widened by 21% since 2017 in emerging Asia. China alone accounts for nearly half the region's gap Key Drawback: Rising medical costs from 2017 Reasons:Gaps in coverage and access Agencies Explore courses from Top Institutes in Please select course: Select a Course Category Degree Product Management Artificial Intelligence healthcare Data Science Design Thinking Project Management Data Science Cybersecurity MCA others Data Analytics Management Digital Marketing Leadership Healthcare Operations Management Technology MBA CXO Public Policy Finance Others PGDM Skills you'll gain: Data-Driven Decision-Making Strategic Leadership and Transformation Global Business Acumen Comprehensive Business Expertise Duration: 2 Years University of Western Australia UWA Global MBA Starts on Jun 28, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Knee pain prices might surprise you Knee pain | search ads Find Now Undo 2024 More Indian households experienced difficulty in affording medical costs Despite initiaitives like Ayushman Bharat (2018) and various state insurance schemes, gaps in coverage remain in India Low disposable incomes and inadequate public health infrastructure leave uninsured households vulnerable
Time of India
an hour ago
- Time of India
Thalassemia cases surge in Punjab, account for 6% of national burden
Chandigarh: Punjab has emerged as a significant contributor to the national thalassemia burden, accounting for nearly 6% of all registered cases across the country in 2025. As many as 257 thalassemia patients were registered in the state so far this year, including 87 children under the age of 12. Tired of too many ads? go ad free now Across the country, 4,361 patients were recorded by July 22, 2025, according to official data shared by the Union health ministry in the Rajya Sabha. Thalassemia is an inherited blood disorder in which the body produces an abnormal or insufficient amount of haemoglobin — the protein in red blood cells responsible for carrying oxygen. The disorder leads to the destruction of red blood cells and results in anaemia. Symptoms vary with severity and type, but commonly include fatigue, jaundice, shortness of breath, and growth delays in children. Severe cases may lead to bone deformities, organ enlargement, and other complications, while mild cases may remain asymptomatic. The current numbers mark the first full-scale registry of thalassemia patients since the disease was integrated into the Sickle Cell Portal in 2023. This digital platform enables state govts to upload patient and screening data to support monitoring, follow-up, and early intervention. While states such as Bihar (1,410 patients), Uttar Pradesh (1,546), and Odisha (454) reported higher absolute case counts, Punjab's data is notable because it reported zero cases in 2023 and 2024. The sudden jump in 2025 is attributed to improved reporting mechanisms rather than a surge in disease incidence. The ministry of health and family welfare clarified that state-level registration began after the thalassemia module was added to the Sickle Cell Portal in 2023. Tired of too many ads? go ad free now Punjab has also seen a significant rise in financial allocations under the National Health Mission (NHM) for blood disorders, including thalassemia. In 2024–25, the state was granted Rs 7,024.47 lakh—more than double the Rs 3,148.08 lakh allocated in the previous year. This places Punjab among the top-funded states, following only Maharashtra, Uttar Pradesh, and Tamil Nadu. According to the health ministry, while thalassemia management primarily falls under the purview of respective state and UT govts, the Centre supports preventive and treatment services through the NHM. This includes assistance for blood bank infrastructure, day care centres, medicines, diagnostic labs, awareness campaigns (IEC), and human resource training, based on state-specific programme implementation plans. In partnership with Coal India Limited (CIL), the ministry is also implementing the Thalassemia Bal Sewa Yojana (TBSY). Under this scheme, financial aid of up to Rs 10 lakh is provided for bone marrow transplants (BMT) for eligible patients, funded through CIL's corporate social responsibility (CSR) programme. Seventeen hospitals across India have been empanelled under the scheme to carry out BMT procedures. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the cost of drugs used for thalassemia treatment. Three iron chelation drugs — Desferrioxamine, Deferiprone, and Deferasirox—are provided at public health facilities with pricing governed by the Drugs (Prices Control) Order, 2013. Notably, the ceiling price for Desferrioxamine powder for injection (500 mg), a scheduled formulation, has already been fixed to ensure affordability. MSID:: 122998585 413 |
The Hindu
4 hours ago
- The Hindu
RSS arm seeks clarity on draft guidelines on biosimilars
Swadeshi Jagran Manch (SJM), economic wing of the Rashtriya Swayamsewak Sangh (RSS), urged the Central Drugs Standard Control Organisation (CDSCO), the apex drug regulatory authority, to bring more clarity in its draft guidelines to ensure production of high-quality and cost-effective biosimilars in the country. In a letter to the Director General of CDSCO, SJM sought safeguards for the Indian industry from 'international pressures for regulations' that favour multi-national pharma companies. The CDSCO had recently issued the 2025 draft guidelines on similar biologics, also called biosimilars. 'Though the draft guidelines represent a pivotal advancement in making affordable, life-saving biosimilars accessible to millions of Indians suffering from chronic and life-threatening conditions such as cancer, diabetes, and autoimmune disorders it requires more clarity and direction,' the SJM letter reads. The SJM appreciated the draft guidelines for embracing the '3Rs principle' (replacement, reduction, refinement) as it reflects India's commitment to ethical scientific practices and alignment with global standards for animal welfare. Modern technologies, including in-vitro assays, organ-on-chip models, and computational simulations, provide robust, accurate, and humane alternatives to confirm the safety and biosimilarity of these drugs, it said. 'These methods are often faster and more precise than animal studies, reducing both ethical concerns and development costs,' it added. The organisation, however, noted that the guidelines stipulating that it will be the discretion of the CDSCO to decide whether a requirement of 'additional non-clinical in vivo animal studies' should be waived or not, poses a 'risk' of increasing biosimilar development cost. This provision goes against the practices of the leading regulatory authorities in other countries, it added. 'Prominent regulatory authorities like the UK MHRA, European Medicine Agency (EMA) Health Canada, and USFDA have either eliminated or phased out mandatory animal testing for biosimilars,' SJM said, adding its recommendation that waiving animal studies entirely when comprehensive laboratory tests demonstrate high similarity between a biosimilar and its reference product. Recently, civil societies, in a letter to CDSCO on the draft guidelines on biosimilars, has urged that there is an urgent need to eliminate unnecessary animal studies, and establish clear conditions for requiring comparative clinical trials for affordable biosimilars without compromising safety and efficacy. According to the SJM, the draft guidelines' provision to waive certain clinical trials when biosimilarity is established through analytical and functional studies is a forward-thinking measure, saying this approach can significantly reduce development costs and expedite market entry, which is critical for patients awaiting affordable treatments. However, the lack of explicit criteria in the guidelines for when waivers are permitted introduces ambiguity, potentially leading to inconsistent application and delays as well as 'room for corrupt practices', it said, stressing the need to establish 'clear conditions' for conduct of clinical trials.
